We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.14 | -2.31% | 90.57 | 90.57 | 90.58 | 92.68 | 90.52 | 92.50 | 308,734 | 14:11:46 |
From May 2019 to May 2024
By Inti Landauro
PARIS--The U.S. Food and Drug Administration has granted a priority review to evaluate the request to market Praluent, a new drug intended to treat hypercholesterolemia and developed by pharmaceutical labs Sanofi (SAN.FR) and Regeneron (REGN), the two firms said Monday.
The goal of the priority review is to get a decision on the application to get a biologics license which gives permission to introduce the drug into interstate commerce, within six months, or on July 24, the two firms said in a statement Monday.
Earlier this month, the European Medicines Agency accepted for review a request for market authorization of the drug, also known as alirocumab, the two companies said.
-Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
